Related content

Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer

By                

Oncology Letters, Vol. 9, Iss. 4, 2015-01 ,pp. : 1822-1826

Spandidos Publications

Access to resources Recommend Favorite

Overview of nanoparticle albumin-bound paclitaxel in metastatic breast cancer

By Strauch Demetria Ileana   Moreno-Aspitia Alvaro  

Breast Cancer Management, Vol. 2, Iss. 3, 2013-05 ,pp. : 221-229

Future Medicine

Access to resources Recommend Favorite

Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer

By Moreno-Aspitia Alvaro   Perez Edith A  

Future Oncology, Vol. 1, Iss. 6, 2005-12 ,pp. : 755-762

Future Medicine

Access to resources Recommend Favorite

Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer

By Yonemori Kan   Katsumata Noriyuki   Uno Hajime   Matsumoto Koji   Kouno Tsutomu   Tokunaga Shinya   Yamanaka Yasuhiro   Shimizu Chikako   Ando Masashi   Takeuchi Masahiro   Fujiwara Yasuhiro  

Breast Cancer Research and Treatment, Vol. 89, Iss. 3, 2005-02 ,pp. : 237-241

Springer Publishing Company

Access to resources Recommend Favorite

A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer

By Yardley Denise   Burris Howard   Peacock Nancy   Raefsky Eric   Melnik Marianne   Inhorn Roger   Shipley Dianna   Hainsworth John  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 471-475

Springer Publishing Company

Access to resources Recommend Favorite